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ABSTRACT
This report attempts to frame the debate about clinical administration of sodium
bicarbonate in the setting of lactic acidosis in terms of simple questions. Specifically, we
address why we develop lactic acidosis in some circumstances, how acute lactic acidosis
impairs cardiovascular function and why sodium bicarbonate may have deleterious
effects which limit its utility. We also attempt to explore treatment alternatives to
sodium bicarbonate.
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INTRODUCTION

dehydrogenase to lactate:

The treatment of lactic acidosis remains controversial.
Although many in vitro and animal studies were
performed over the past 40 years, there is still a
dearth of clinical data addressing simple questions
such as whether sodium bicarbonate therapy is
deleterious or beneficial or whether alternative
buffers such as tris (hydroxymethyl)aminomethane
(THAM) or a combination of sodium bicarbonate with
disodium carbonate (Carbicarb) offer advantages to
patients. In this report we will attempt to highlight
the key issues that may be useful in the design of
subsequent clinical treatments and studies. To this
end, we plan to frame and answer some very simple
questions.
WHY DO WE GENERATE LACTIC ACIDOSIS?
The end product of anaerobic glycolysis is pyruvate,
which can be metabolized to carbon dioxide by the
energy efficient Krebs cycle in the mitochondria.
Alternatively, pyruvate can be metabolized by an
energy inefficient pathway by the enzyme lactate
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(Pyruvate + NADH + H+ <—> lactate + NAD+)
Lactic acidosis, one consequence of the shock state is
associated with cellular dysfunction and is a predictor
of mortality and morbidity.1-3 Together with diabetic
ketoacidosis, it accounts for approximately 85% of
the cases of acute severe metabolic acidosis.4 The
major causes of lactic acidosis are typically divided
into disorders associated with tissue hypoxia (type
A) and disorders in which tissue hypoxia is absent
(type B). Cardiogenic or hypovolemic shock, severe
heart failure, severe trauma and sepsis are the
most common causes of type A lactic acidosis.5
Normally, approximately 1400 mmol of lactic acid
are produced daily, primarily by skeletal muscle
and gut. The production of lactic acid is balanced
by the metabolism of an equivalent amount of the
compound in the liver, which constitutes the Cori
cycle. Other tissues including the kidneys are capable
of metabolizing lactate as well. In humans, the
kidneys contribute approximately 10-20% of lactate
removal.6 On the other hand, tissue hypoxia results
in excessive lactate production which can increase
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under pathological conditions nearly 100 fold.6

discuss below.

Lactate removal takes place via its oxidation to
pyruvate by lactate dehydrogenase. Pyruvate may
be either oxidized to carbon dioxide producing
energy or transformed into glucose through
gluconeogenesis. Pyruvate oxidation requires
oxygen supply and the cooperation of pyruvate
dehydrogenase, the tricarboxylic acid cycle, and
the mitochondrial respiratory chain. Congenital or
acquired deficiencies in gluconeogenesis including
tissue hypoxia may induce lactate accumulation.7
Impaired mitochondrial oxidative function, as occurs
in hypoxic states, leads to accumulation of pyruvate in
the cytosol and thus to increased lactate production.
The accumulation of pyruvate in the hypoxic state
reflects both overproduction of pyruvate and reduced
utilization of pyruvate through its two pathways,
the oxidative decarboxylation to acetyl-coenzyme A
(acetyl-CoA) and gluconeogenesis.8

Several cellular and functional processes have
been implicated in the pathogenesis of cardiac
contractile dysfunction in severe acidemia. These
include impairment of energy production,15,17
disturbances in intracellular calcium transport and
cycling,18-24 and impairment of actin-myosin crossbridge cycling by inorganic phosphate (Pi) and
H⁺ accumulation.25 In myocardial cells metabolic
acidosis results in increased energy demand that
exceeds energy production.15 This discrepancy
between demand and production of energy is
evidenced by decreases in creatinine phosphate
(PCr) and reciprocal increases in inorganic
phosphate (Pi) beyond what would be expected
from the calculated increases in [H+].16 The decrease
in energy production in the isolated perfused
heart appears to be the result of inhibition of the
mitochondrial oxidative phosphorylation more than
direct effects on glycolysis through allosteric effects
on phosphofructokinase.17

IS THE DEVELOPMENT OF ACIDOSIS A “BAD”
THING?
Clearly there are some “good” things about acidosis.
On a tissue level, a moderate degree of acidosis
allows for greater delivery of oxygen, the shortage of
which often underlies the basic pathophysiology of
lactic acidosis (see above). Acidosis also appears to
decrease the ongoing rate of lactic-acid generation
(or ketoacid generation). This negative feedback
attenuates the net degree of acidemia.9
However, if we examine the effect of acidosis on the
heart and the vascular system, one must conclude
that it is generally deleterious. In cardiac cells, the
drop in intracellular pH is known to have deleterious
effects on myocardial contractile function.9-11 This
has been clearly shown in the isolated perfused
rat heart.12 Schotola, et al studied the effect of
incremental dose of the beta agonist isoproterenol
on human ventricular trabeculae at pH 7.20 and 7.40.
They observed a reduction in cardiac contractility and
rightward shift of the isoproterenol dose response
curve at pH 7.20.13,14 In intact animals, compensatory
mechanisms related to the neuroendocrine response
initially maintain cardiac output, but ultimately
cardiac output falls with severe acidosis15,16 as we
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Intracellular pH also has a considerable impact
on the amplitude of the systolic calcium transient
and subsequent excitation-contraction coupling
pathway. The net impact of intracellular acidosis
is an increase in the calcium transient amplitude
due to increased sarcoplasmic reticulum calcium
content which subsequently affects the excitationcontraction coupling pathway. It was also
demonstrated that global acidosis or ischemia
modifies Cai2+ cycling in myocytes causing a rise in
the diastolic Cai2+ and prolongation of the cellular
calcium transient characterizing a potential proarrhythmic state.26
As mentioned earlier, it is apparent that the
sympathoadrenal system constitutes an important
aspect of the heart’s response to acidosis.27
Increased release of catecholamines in response to
the acidic environment from cardiac nerve endings
and adrenal medulla was observed but myocardial
responsiveness to catecholamines was found to
be altered along with markedly enhanced vagal
stimulation.28-32 Mitchell et al demonstrated that
in moderate acidosis (pH > 7.2), there is actually
an increase in the maximal rate of left ventricular
pressure (max dp/dt) and stroke volume related to
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the increased catecholamine levels, but with severe
acidosis, the contractile state of the left ventricle is
significantly depressed.27 Teplinsky and colleagues
showed that experimental lactic acidosis caused a
40% reduction in stroke volume without reducing
venous return in animals suggesting impaired
myocardial contractility.33 Davies demonstrated that
human beta 2-adrenergic receptors were altered
in an in vitro model of lactic acidosis accompanied
by resistance to the inotropic and vasoconstrictive
effects of infused catecholamines.34 In another study
by Kellum and colleagues, moderate and severe
acidosis caused hypotension in animals without
affecting plasma levels of inflammatory markers.35
Conduction abnormalities which predispose to
ventricular arrhythmias are often found in animal
models of metabolic acidosis. This finding can
explain the ventricular irritability observed during
myocardial ischemia.36
IF ACIDOSIS IS “BAD,” WHY ISN’T THE
ADMINISTRATION OF SODIUM BICARBONATE
“GOOD?”

lactate production by the splanchnic bed.37 Graf
et al38 compared the effect NaHCO3 therapy in
dogs with hypoxic lactic acidosis with the effects
of sodium chloride or no therapy. Treatment with
NaHCO3 was associated with decreases in cardiac
output and blood pressure compared with the other
two groups. Moreover and despite the infusion
of NaHCO3, both arterial pH and bicarbonate
concentration decreased by a similar amount in
all three groups of dogs. This was postulated to
result primarily from a paradoxical intracellular
acidosis resulting from the rapid equilibrium of
CO2 across the cell membrane and the delayed
equilibration of bicarbonate.39 Other possible
adverse effects of sodium bicarbonate therapy
include hypertonicity and delayed metabolic
alkalosis,32,40 but the paradoxical intracellular
acidosis is probably the most important. Graf and
colleagues measured intracellular liver pH with DMO
distribution and found bicarbonate actually lowered
this value in their animal model.38 This has been
confirmed using other methods of intracellular pH
determination.12,15,16,41 To fully understand this, we
can look at what happens when the bicarbonate

It is very clear that therapy directed to the specific
cause of the acidosis is rational. Clinical outcomes
are in fact quite good when such intervention
effectively normalizes the production
of acid as is the case with diabetic
ketoacidosis and some cases of toxic
alcohol ingestion where the process of
organic acid production can be stopped.
On the other hand, conditions presenting
with type A lactic acidosis and associated
circulatory disturbances and tissue
hypoxia as in sepsis or cardiac arrest
seem to require addressing the acidosis
directly. In fact, given the potential
deleterious effects of severe acidosis,
some experts recommend intravenous
sodium bicarbonate therapy although its
value in reducing mortality or improving
hemodynamics remains unproven.5
Questioning the utility of bicarbonate
therapy began in the late 1970s with the observation
in experimental lactic acidosis that bicarbonate
therapy worsened outcomes. In animal models of
lactic acidosis, administration of NaHCO3 increased
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FIGURE 1: Schematic illustrating effects of sodium bicarbonate (HCO3-) administration into an
acidotic milleiu. Other abbreviations: H+ - protons,
H2CO3 carbonic acid, CO2 –
carbon dioxide, CA – carbonic anhydrase.
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buffer system is open vs. closed.
In an open system (i.e., when tissue perfusion
and pulmonary ventilation is adequate), CO2
tension is controlled by the brain stem through
respiratory drive and the CO2 which is generated
from oxidative metabolism of carbon containing
organic compounds and the dehydration of H2CO3
by carbonic anhydrase (figure 1) is eliminated by the
lungs. This has been shown in both experimental
animals42 and humans43. Such a system can be
modelled experimentally using an instrument called
a tonometer where the CO2 tension can be held
constant.44 However, when tissue perfusion and/or
pulmonary ventilation are compromised as occurs
during circulatory shock, the clinical scenario more
closely approximates a closed system. A simple
model for a closed system is a glass syringe with a
gas tight rubber stopper.45
Kimmoun et al46 investigated the cardiovascular and
metabolic effects of an adaptive sodium bicarbonate
therapy, including ventilation of CO2 increase with
hyperventilation and ionized calcium decrease with
calcium administration. Their strategy normalized
extra- and intracellular pH, improved cardiac
elastance and improved aortic and mesenteric
vasoactivity compared with controls. Small studies
have shown promising results when high dose
bicarbonate was administered via continuous
venovenous hemofiltration to treat acidosis and
renal failure.47,48 The harmful effect of bicarbonateinduced widespread intracellular acidosis on
cellular and metabolic function, particularly the
heart, suggests that alternative buffers compatible
to bicarbonate but without the CO2 generating
potential might offer clinical advantages.
ALTERNATIVE BUFFERS
In an effort to overcome the side effects of
sodium bicarbonate, other alkali therapies have
been developed. THAM, (tris-hydroxymethylaminomethan), dichloroacetate and Carbicarb
constitute the most prominent molecules in this
context. THAM was first introduced into clinical
practice in 1959.49 30% of this compound exists
in the nonionized form where it can penetrate cells
and thereby raise the intracellular pH by buffering
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protons by virtue of the ammonia moiety.40 In
experimental studies, THAM was found to have
a comparable buffering capacity to bicarbonate
but without intracellular acidosis.50 Moreover,
THAM was found to have a favorable effect on
myocardial contractility when used in dogs with
lactic acidosis51 as well as in perfused isolated heart
model during metabolic acidosis52 (pH=7.0).
Clinical trials assessing THAM in patients with lactic
acidosis are limited. Hoste and colleagues showed
that administration of THAM to patients in ICU with
mild metabolic acidosis was as effective as sodium
bicarbonate.53 Further studies looking at outcome
and cardiovascular function are needed to examine
the use of THAM in the treatment of acute metabolic
acidosis. THAM has considerable side effect profile
including hepatic failure and hyperkalemia.
Moreover, THAM is excreted by the kidney in its
protonated form. Therefore, its usefulness would
appear to be limited to acidosis in the presence of
significant renal failure.40
Dichloroacetate (DCA) is another investigational
drug that has been studied in lactic acidosis.
DCA exerts multiple effects on pathways of
intermediate metabolism resulting in stimulation
of peripheral glucose utilization and inhibition
of gluconeogenesis.54 In lactic acidosis, DCA is
believed to facilitate the oxidation of lactate by
stimulating the activity of pyruvate dehydrogenase.
In healthy volunteers during incremental exercise,
DCA resulted in the reduction of blood lactate
accumulation accompanied by reduction in
pulmonary CO2 output without enhancing exercise
tolerance.55 However, in a randomized controlled
trial in patients with lactic acidosis, DCA resulted in
statistically significant but clinically unimportant
changes in arterial-blood lactate concentrations
and pH and fails to alter either hemodynamics
or survival.56 DCA is not currently available in the
United States for clinical use.
Carbicarb, a mixture of equimolar quantities of
sodium bicarbonate and sodium carbonate was first
formulated in 1983 by Filley and Kindig.57 Sodium
carbonate in the mixture reacts with carbonic acid
(H2CO3) to generate bicarbonate via the following
reaction.45,57
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CO3- ² + H2CO3 <—> 2 HCO3Thus, the carbonate component of Carbicarb
consumes CO2 while the HCO3- component and
the newly generated HCO3- will form CO2 when
protons are buffered. At the cellular level, systemic
[administration of ] Carbicarb to treat severe
acidosis resulted in systemic alkalinization without
major changes in PaCO2 and intracellular pH in
hepatocytes16, isolated heart12,58,59 and brain cells41
compared with NaHCO3 therapy which resulted in
paradoxical intracellular acidosis. In animals [with
lactic acidosis], Carbicarb was found to be superior to
NaHCO3 with improved tissue pH, lactate production
and cardiac hemodynamics.60 In healthy volunteers,
Carbicarb was associated with transient decrease in
PaCO2 compared with sodium bicarbonate.43
In a study of 36 patients undergoing surgery who
developed mild acidosis, Carbicarb was found to
be safe and comparable to NaHCO3.61 Controlled
studies of the impact of Carbicarb in patients with
severe acidosis have not been reported and the drug
is not currently available in the United States.
Carbicarb is an efficient buffer that does not cause
intracellular acidosis. It has the potential for treating
acute acidosis without impairing cellular and cardiac
function. Each molecule of CO3-²will effectively
eliminate one hydrogen ion in the blood, thereby
directly lowering the proton concentration and
raising pH. In addition, HCO3-, the product of
CO3-² buffering is the main component of the
sodium bicarbonate solution that is safe in humans
and has excellent cellular permeability. On the other
hand, Carbicarb can be damaging to the adjacent
tissues after injection due to its hypertonic nature
and the high level of alkalinity.62 Moreover, stability
problems with the mixture and the proposed
delivery syringe have slowed its entry into the clinic.
Specifically, the extremely high pH of Carbicarb
appears to degrade the rubber stoppers which
can safely be used to seal bicarbonate ampules
(unpublished observations).
SIMULATIONS OF DIFFERENT COMBINATIONS OF
BICARBONATE AND CARBONATE
As mentioned above, Carbicarb, like THAM, was
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developed with the aim of avoiding “paradoxical”
intracellular acidosis. To examine what changes in
PaCO2 and pH might be anticipated, we performed
the following simulations guided by the observed
responses seen with closed and open systems.45
Specifically, we found in the past that when
bicarbonate was added to a closed system, we
observed very little change in pH but rather marked
increases in PaCO2. In contrast, the addition of
carbonate to a closed system resulted in the rapid
consumption of CO2 as new HCO3 was generated.
Using these principles and the known values for
CO2 solubility and the equilibrium constant for the
H2CO3 – HCO3- system, simulations were performed
using the programming language MatlabTM
(R2014a, the Mathworks, Inc.,) using code detailed in
Appendix 1.
We first examined the effects of NaHCO3 addition
in an “open” system where PaCO2 was maintained
at 40 torr. Bicarbonate caused no changes in PaCO2
(by definition, figure 2a) and increase in final pH in
proportion to the change in HCO3- (figure 2b). In
such a system, addition of carbonate was twice as
potent as bicarbonate as the reaction CO3-² + CO2
—> 2 HCO3- predicted, but no qualitative differences
were noted (data not shown). In contrast, when
bicarbonate was added to a closed system, increases
in PaCO2 were seen in proportion to the initial [H+]
with essentially no change in pH as we observed
in the aforementioned experimental publication45,
(figures 2c and 2d, respectively). Disodium carbonate
however was a very effective alkalinizing agent
over a wide range of pH values (figure 3 panel a and
b). When we looked at varying the proportion of
carbonate to bicarbonate in a mixture, it appeared
that CO2 neutrality was achieved at relatively low
proportions of carbonate, especially when the initial
PaCO2 was high (figure 4, panels a and b).
CONCLUSIONS
It is very clear that, while cardiovascular function
is embarrassed by acute lactic acidosis, treatment
with sodium bicarbonate may have deleterious
effects that appear largely related to its propensity
to generate CO2 in a closed system. As there is no
accepted methodology for assessing whether the
patient’s milieu is more closely approximated by
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FIGURE 2A

FIGURE 2C

FIGURE 2B

FIGURE 2D

FIGURE 2: Simulated changes in PaCO2 and pH in open and closed system following addition of
HCO3- (0 – 10 meq/l) with starting PaCO2 of 40 torr and initial pH (6.4 to 7.0). Panels
2a and 2b show PaCO2 and pH (respectively) in open system and Panels 2c and 2d show PaCO2 and pH (respectively) in
closed system.
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FIGURE 3A

FIGURE 3B

FIGURE 3: Simulated changes in PaCO2 (Panel 3a) and pH (Panel 3b) in a closed system following
addition of disodium carbonate (0-4 mmol/l) with initial pH varied between 6.4 and 7 with initial PaCO2 of 100 torr.

FIGURE 4A

FIGURE 4B

FIGURE 4: Simulated changes in PaCO2 (Panel 4a) and pH (Panel 4b) in a closed system following
addition of a mixture of disodium carbonate and sodium bicarbonate (total 2 mmol/l of carbonate + bicarbonate) with
initial pH varied between 6.4 and 7 with initial PaCO2 of 100 torr.
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a closed or an open system, it is very difficult to
advise physicians whether or how to administer
sodium bicarbonate in the clinical setting of lactic
acidosis. Although some experimental buffers have
been developed which appear promising, further
clinical proof is necessary before their use can be
advocated. Our simulations showed that solutions
containing carbonate to bicarb ratios less than 1:1
might be useful In treating lactic acidosis. It needs to
be examined if these solutions with different ratios
will differ from carbicarb in terms of stability and
administration issues.”
APPENDIX 1: MATLABTM CODE
%bicarbonate addition simulation open
for i=1:100
HCO3m(i)=4+i/10;
aHCO3(i)=i/10;
pCO20=40;
end
for i=1:100
for j=1:100
pH(i,j)=6.1+log10(HCO3m(i)+ aHCO3(j))/1.2;
pCO2(i,j)=40;
end
end
mesh(aHCO3,pH(:,1),pH)
axis([0 10 6.6 7.2 6.6 7.2])
xlabel(‘added bicarbonate (mmol/l)’)
ylabel(‘initial pH’)
zlabel(‘final pH’)
figure
mesh(aHCO3,pH(:,1),pCO2)
axis([0 10 6.6 7.2 30 150])
xlabel(‘added bicarbonate (mmol/l)’)
ylabel(‘initial pH’)
zlabel(‘final PaCO2 (torr)’)
%bicarbonate addition simulation open
for i=1:100
HCO3m(i)=14+i/10;
aHCO3(i)=i/10;
pCO20=140;
pH(i,1)=6.1+log10(HCO3m(i)/(pCO20*0.03));
end
for i=1:100
for j=1:100
pCO2(i,j)=((HCO3m(i)+aHCO3(j))*10^-pH(i,1))/
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(0.03*10^(-6.1));
pH(i,j)=6.1+log10(HCO3m(i)/(0.03*pCO2(i,j)));
end
end
mesh(aHCO3,pH(:,1),pH)
%axis([0 10 6.6 7.2 6.6 7.2])
xlabel(‘added bicarbonate (mmol/l)’)
ylabel(‘initial pH’)
zlabel(‘final pH’)
figure
mesh(aHCO3,pH(:,1),pCO2)
%axis([0 10 6.6 7.2 30 150])
xlabel(‘added bicarbonate (mmol/l)’)
ylabel(‘initial pH’)
zlabel(‘final PaCO2 (torr)’)
%carbonate addition simulation closed
pCO20=140;
keq=1.2/((40e-6)*24);
for i=1:100
HCO3m(i)=8+i/10;
CN(i)= i/25;
end
for i=1:100
for j=1:100
x=pCO20*0.03;
a=HCO3m(i)+ 2*CN(j);
z=6.1+log10(a/x);
x=x-CN(j);
z=6.1+log10(a/x);
x=1000*a*keq*10^-z;
z=6.1+log10(a/x);
x=1000*a*keq*10^-z;
pH(i,j)=z;
PCO2(i,j)= x/0.03;
end
end
mesh(CN,pH(:,1),pH)
%axis([0 1.0 6.6 7.2 6.6 8.0])
xlabel(‘added carbonate (mmol/l)’)
ylabel(‘initial pH’)
zlabel(‘final pH’)
figure
mesh(CN,pH(:,1),PCO2)
%axis([0 1.0 6.6 7.2 0 40])
xlabel(‘added carbonate (mmol/l)’)
ylabel(‘initial pH’)
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zlabel(‘final PaCO2 (torr)’)
%mixture of carbonate/bicarbonate closed
pCO20=140;
keq=1.2/((40e-6)*24);
d=input(‘enter dose of bicarbonate/carbonate
mixture’);
%set up intial bicarb concentrations and fraction of
carbonate
for i=1:100
HCO3m(i)=12+i/10;
FCN(i)= (i-1)/100;
end
% develop simulations
for i=1:100
for j=1:100
% initial H2CO3
x=pCO20*0.03;
%reaction of carbonate with CO2 generating
new bicarbonate
a=HCO3m(i)+ 2*d*FCN(j);
% new pH
z=6.1+log10(a/x);
% reduction in CO2 tension from carbonate
x=x-2*d*FCN(j);
%new pH
z=6.1+log10(a/x);
%new H2CO3 based on bicarbonate addition
x=1000*a*keq*10^-z;
%new pH
z=6.1+log10(a/x);
%recalculate H2CO3
xx=1000*(a+d*(1-FCN(j)))*keq*10^-z;
%recalculate pH
z=6.1+log10(a/xx);
%enter data into matrices
pH(i,j)=z;
PCO2(i,j)= xx/0.03;
end
end
%plots
mesh(FCN,pH(:,1),pH)
%axis([0 1.0 6.6 7.2 6.6 8.0])
xlabel(‘fraction carbonate’)
ylabel(‘initial pH’)
zlabel(‘final pH’)
figure
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mesh(FCN,pH(:,1),PCO2)
%axis([0 1.0 6.6 7.2 0 40])
xlabel(‘fraction carbonate’)
ylabel(‘initial pH’)
zlabel(‘final PaCO2 (torr)’)
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